Clinical Trial Update: Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Irritable Bowel Syndrome [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluated the efficacy of an encapsulated probiotic, Bifidobacterium infantis 35624, for irritable bowel syndrome. The study was sponsored by…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• Bifidobacterium infantis 35624 (Bifidobacterium infantis 35624)

Snippet

Sponsor: Procter and Gamble | Conditions: Irritable Bowel Syndrome | Phase 3 | Status: COMPLETED